Date Announced:
Total Deal Value:
Upfront Cash:
Upfront Equity:
Option Payments:
Total Milestones:
Royalties:
Cost & Profit Split:
The Asset:
Deal Structure:
Partnership Features:
Deal Details:
Last Month:
Congrats to SpringWorks and GSK for landing DealForma’s September 2022 Top Biopharma Deal. Last month’s Deal of the Month was Sanofi – Innovent for antibody-conjugate drug SAR408701 for the treatment of non-small cell lung cancer (NSCLC). Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Licensing Deals
Funding Rounds
M&A
Company Profiles
Other Deals
Drug Sales Figures
Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...
We are tracking the biopharma R&D partnerships in neurology through the first half of 2023. Some notable licensing deals include Voyager's partnership with Neurocrine, which secured an upfront payment of $175 million and the potential to achieve up to $4.2 billion...
